Cancer Genetics, Inc. to Present at Two Upcoming Investor Conferences During September

RUTHERFORD, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will participate in two investor conferences being held in New York City next week. On Tuesday, September 27, 2016, CGIX will present at the Ladenburg Thalmann 2016 Healthcare Conference. On Wednesday, September 28, 2016, CGIX will present at the INVESTfest 5th Annual Investors Conference in partnership with Joseph Gunnar & Company.

Ladenburg Thalmann 2016 Healthcare Conference | New York City
Company Presentation:
Date: Tuesday, September 27, 2016
Time: 12:00 pm ET

OktoberINVESTfest 5th Annual Investors Conference | New York City
Company Presentation:
Date: Wednesday, September 28, 2016
Time: 9:10 am ET

A replay of the webcasts will be available on the Cancer Genetics website’s events page for 90 days following the presentation.

Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:
Twitter: @Cancer_Genetics

Forward-Looking Statements: 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding future financial and/or operating results and potential for our tests and services, and future revenues or growth in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended June 30, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

CONTACT: Contact:

Panna Sharma
Cancer Genetics, Inc.